Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD4059 SAD in Healthy Subjects
NCT05653037Phase 1Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in thrombosis comparing RBD4059 SAD experimental group with Placebo SAD group (2 arms). Primary endpoint: Treatment Related Adverse Events. Started Mar 2023; status: completed.
02
Drugs
RBD4059
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT05653037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653037.